Bicara Therapeutics (BCAX) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 42.9% versus a loss of 4.1%. Damora Therapeutics is the larger company by market cap ($1.30 billion vs $1.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | DMRA |
|---|---|---|
| Share price | $17.50 | $21.08 |
| Market cap | $1.16B | $1.30B |
| 1-day change | +1.39% | +2.53% |
| YTD return | +2.55% | -8.39% |
| 1-year return | -4.11% | +42.92% |
| 5-year return | — | -75.35% |
| EPS (TTM) | $-3.12 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $38.33 |
| 52-week low | $13.70 | $4.95 |
| Distance from 52-week high | -43.53% | -45.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +102.86% | +122.44% |
| Average volume | 623.79K | 535.42K |
| Shares outstanding | 66.17M | 61.74M |
| Employees | 103 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed BCAX by 47.0 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BCAX vs DMRA FAQ
Which is bigger, Bicara Therapeutics or Damora Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.30B compared with $1.16B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or DMRA?
DMRA returned +42.92% over the past 12 months, compared with -4.11% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.